Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Lung Cancer. 2018 Jan;115:28-33. doi: 10.1016/j.lungcan.2017.11.014. Epub 2017 Nov 16.
The objective of this study was to investigate clinicopathological risk factors for local recurrence in patients who underwent either complete resection with lobectomy or more extensive resection with hilar and mediastinal lymph node dissection for non-small cell lung cancer (NSCLC). The role of adjuvant therapy was also explored.
We reviewed the records of 1012 consecutive stage I-III NSCLC patients who underwent complete resection. The median follow-up time was 59 months. The risk factors for local recurrence were investigated by multivariate analysis using Cox's proportional hazards regression model.
Local recurrence was identified in 9.4% of the patients. The most significant risk factor for local recurrence was lymph node metastasis (N1: hazard ratio [HR]=2.27, p=0.009; N2: HR=6.85, p<0.0001). For the subgroup of patients with lymph node metastasis (n=289), the independent risk factors for local recurrence were N2 disease with N1 metastasis (N2 with N1; HR=3.46, p<0.0001) and non-receipt of adjuvant platinum-based chemotherapy (HR=1.91, p=0.018). The 5-year freedom from local recurrence rates were 96.1%, 84.1%, 85.0%, and 53.5% for N0, N1, skip N2, and N2 with N1 stages (p<0.0001).
Local recurrence is significantly associated with poor overall survival. Therefore, local control is essential for radical cure of NSCLC. N2 with N1 status was the primary risk factor for local recurrence, while adjuvant chemotherapy improved local control. These data have important implications for postoperative radiotherapy and highlight the need to devise more effective eligibility criteria for this modality in patients with lymph node metastasis.
本研究旨在探讨行肺叶切除术或更广泛的肺门和纵隔淋巴结清扫术治疗非小细胞肺癌(NSCLC)的患者中,局部复发的临床病理危险因素。还探讨了辅助治疗的作用。
我们回顾了 1012 例连续接受完全切除术的 I-III 期 NSCLC 患者的记录。中位随访时间为 59 个月。使用 Cox 比例风险回归模型的多变量分析来研究局部复发的危险因素。
9.4%的患者发生了局部复发。局部复发的最显著危险因素是淋巴结转移(N1:风险比[HR]=2.27,p=0.009;N2:HR=6.85,p<0.0001)。对于有淋巴结转移的患者亚组(n=289),局部复发的独立危险因素是 N2 伴 N1 转移(N2 伴 N1;HR=3.46,p<0.0001)和未接受辅助含铂化疗(HR=1.91,p=0.018)。N0、N1、跳跃性 N2 和 N2 伴 N1 期患者的 5 年无局部复发率分别为 96.1%、84.1%、85.0%和 53.5%(p<0.0001)。
局部复发与总体生存率显著相关。因此,局部控制对于 NSCLC 的根治性治疗至关重要。N2 伴 N1 状态是局部复发的主要危险因素,而辅助化疗改善了局部控制。这些数据对术后放疗具有重要意义,并强调需要为有淋巴结转移的患者制定更有效的选择标准。